Dr. A. Michael Lincoff stands as a preeminent leader in cardiovascular medicine and clinical research at the globally renowned Cleveland Clinic, which maintains the nation's top-ranked cardiovascular program. He currently serves as Vice Chairman of the Department of Cardiovascular Medicine and Director of the Cleveland Clinic Coordinating Center for Clinical Research, an academic organization dedicated to managing multicenter clinical trials of novel pharmacologic and device therapies. Holding the distinguished Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research, Dr. Lincoff's career trajectory reflects a purposeful transition from engineering to medicine, having earned his B.S. in Chemical and Biomedical Engineering from Carnegie Mellon University before completing his medical degree at Johns Hopkins University. His specialized training encompassed internal medicine residency at Beth Israel Hospital, cardiovascular disease fellowship at the University of Michigan, and interventional cardiology fellowship at the Cleveland Clinic itself.
Dr. Lincoff's research has profoundly shaped contemporary approaches to coronary intervention through his focused work on developing therapies to reduce acute and long-term complications of percutaneous coronary revascularization procedures. As principal investigator or steering committee member for over 20 pivotal clinical trials in ischemic heart disease, his research has collectively enrolled nearly 100,000 patients, studying innovative antithrombotic and metabolic agents across diverse cardiovascular conditions. His scientific contributions have directly influenced evidence-based clinical practice guidelines for acute coronary syndromes and atherosclerosis management, with findings published in the field's most prestigious medical journals. The translational impact of his work extends to regulatory decision-making, where his clinical trial leadership has informed therapeutic advancements that improve outcomes for millions of cardiovascular patients worldwide.
Beyond his clinical and research leadership, Dr. Lincoff chairs the Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug Administration, playing a critical role in evaluating scientific evidence for drug approval decisions that affect cardiovascular care nationally. He has received significant recognition including the Maria and Sam Miller Professional Excellence Award for Scientific Achievement in Clinical Research from the Cleveland Clinic Foundation. As an active editor for numerous peer-reviewed journals and supervisor of all human subjects research throughout the Cleveland Clinic Health System, he maintains substantial influence over both scientific discourse and research standards in cardiovascular medicine. Dr. Lincoff continues to advance innovative research initiatives focused on optimizing therapeutic approaches for patients with acute coronary syndromes while mentoring the next generation of cardiovascular researchers and clinicians.
